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Abstract
With Alzheimer’s disease (AD) exhibiting reduced ability of neural stem cell renewal, we hypothesized that de novo
mutations controlling embryonic development, in the form of brain somatic mutations instigate the disease. A leading gene
presenting heterozygous dominant de novo autism-intellectual disabilities (ID) causing mutations is activity-dependent
neuroprotective protein (ADNP), with intact ADNP protecting against AD-tauopathy. We discovered a genomic autism
ADNP mutation (c.2188C>T) in postmortem AD olfactory bulbs and hippocampi. RNA-Seq of olfactory bulbs also
identified a novel ADNP hotspot mutation, c.2187_2188insA. Altogether, 665 mutations in 596 genes with 441 mutations in
AD patients (389 genes, 38% AD—exclusive mutations) and 104 genes presenting disease-causing mutations (OMIM) were
discovered. OMIM AD mutated genes converged on cytoskeletal mechanisms, autism and ID causing mutations (about 40%
each). The number and average frequencies of AD-related mutations per subject were higher in AD subjects compared to
controls. RNA-seq datamining (hippocampus, dorsolateral prefrontal cortex, fusiform gyrus and superior frontal gyrus—
583 subjects) yielded similar results. Overlapping all tested brain areas identified unique and shared mutations, with
ADNP singled out as a gene associated with autism/ID/AD and presenting several unique aging/AD mutations. The large
fusiform gyrus library (117 subjects) with high sequencing coverage correlated the c.2187_2188insA ADNP
mutation frequency to Braak stage (tauopathy) and showed more ADNP mutations in AD specimens. In cell cultures, the
ADNP-derived snippet NAP inhibited mutated-ADNP-microtubule (MT) toxicity and enhanced Tau–MT association. We
propose a paradigm-shifting concept in the perception of AD whereby accumulating mosaic somatic mutations promote
brain pathology.
Introduction
Adult neurogenesis in humans takes place exclusively in the
dentate gyrus of the hippocampus and in the subventricular
zone of the olfactory bulb, while newborn neurons migrate to
other brain regions. Impaired adult neurogenesis, implicated
in Alzheimer’s disease (AD), is underlined by reduced ability
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for neural stem cell renewal in these brain tissues [1, 2].
Chromosomal changes usually associated with aberrant
developmental processes are also found in the aging brain [3]
and we now asked whether rare developmental de novo
mutations might also be found in the form of somatic muta-
tions in the aging brain.
In ~0.17% of the autism-intellectual disabilities (ID)
cases, activity-dependent neuroprotective protein (ADNP)
[4, 5] is mutated de novo [6, 7], representing one of the
most prevalent mutated heterozygous dominant genes
leading to autism/ID [8–10]. ADNP [4] is critical for neu-
rogenesis [11] essential for brain formation [12] and func-
tion [13], controlling hundreds of key regulatory genes
in vivo [13, 14]. As such, ADNP mRNA content dysregu-
lation has been implicated not only in autism [15–17] but
also in schizophrenia [18, 19], Parkinson’s disease [20] and
AD [13, 20, 21]. Thus, complete proteomics revealed
ADNP as a unique protein decreasing in AD patient serum
samples [22], and a positive correlation was found between
ADNP serum content and elderly subject performance in IQ
tests [20]. Furthermore, ADNP directly regulates the
expression of apolipoprotein E (APOE) [13], in a sex-
dependent manner [21], with APOE4 being the major risk
gene for sporadic AD.
The most devastating outcome of AD is dramatically
decreased cognition. The progression of the disease is
measured as decreases in cognitive abilities, which cor-
respond to increases amyloid plaque burden, Tau pathol-
ogy and brain degeneration, with AD being the most
prevalent tauopathy [15]. ADNP deficiency has been
associated with aging-related increase in tauopathy with
Adnp+/- mice exhibiting age-driven tauopathy, neurode-
generation, and cognitive deficits [13]. An eight-amino-
acid peptide, NAP (NAPVSIPQ), identified as the smal-
lest active snippet of ADNP, protects against ADNP
deficiencies [13], including tauopathy [23] and cognitive
deficits [24] and displays potent neuroprotection against
multiple toxic insults [4]. NAP (also known as davune-
tide, or CP201) was identified as a neurotrophic factor,
stimulating synapse formation through microtubule (MT)
interaction [23, 25].
MTs are the major component of the neuronal cytos-
keleton. MT dynamics plays a key regulatory role during
axon outgrowth and regeneration. MTs are decorated by
MT-associated proteins (MAPs) and MT plus-end track-
ing proteins (+TIPs), which concentrate and act at
growing MT ends. Numerous+TIPs localize to MT plus-
ends in MT-end-binding-proteins (EBs)-dependent man-
ner [26]. Together, EBs and the related+TIPs regulate
MT dynamics and MT connection to cellular
structures, and thus determine the fate of MT growing
ends [27].
We discovered direct interactions of ADNP with the EB
family of proteins and showed that EB1 and EB3 are
binding targets for NAP through the SIP motif on ADNP/
NAP (NAPVSIPQ). In this respect, NAP enhances
ADNP–EB3 interaction [25], and EB3 silencing inhibits
NAP-driven dendritic spine formation [25]. Furthermore,
NAP/ADNP by binding to EB3, which in turn binds Tau,
enhance Tau association with the MT shaft, protecting the
MTs [23, 28], MT-regulated axonal transport [14] and
inhibiting tauopathy [13, 29].
Here, we concentrated on three previous findings. (1)
The ADNP syndrome, like AD, is characterized by ID. (2)
Neurogenesis/synaptic plasticity is impaired in autism and
AD and ADNP is critical for both. (3) Intact ADNP is
required for MT dynamics and stability through Tau
interactions, while AD is characterized by shorter MTs
[30] and tauopathy [15]. We therefore hypothesized de
novo somatic rare mutations of ADNP as not only
occurring during early development but also arising in a
mosaic form in the aging brain and affecting AD pre-
cipitation and progression. Furthermore, given the pro-
tection of NAP against Adnp haploinsuffiency [13], we
conjectured NAP protection against mutated-ADNP
associated MT deficiencies.
Using postmortem AD and control brains (olfactory
bulbs and hippocampi), we revealed a hotspot for
somatic AD ADNP mutations including the novel fra-
meshift, c.2187_2188insA, p.Arg730Thrfs*4 with
mutation frequency correlated to Braak stage (tauopathy)
and aging. Combined with public datamining of RNA-
seq results from hippocampi, dorsolateral prefrontal
cortex (DLPFC), fusiform gyri, and superior frontal
gyrus, we identified pathogenic mutations in >9000
genes, with a third representing brain region unique AD
mutations including autism/ID and cytoskeletal
functions. These findings present a novel molecular
understanding of AD.
Methods
RNA and DNA extraction
Postmortem tissue samples from elderly donors (20 con-
trols, 20 AD patients), all exhibiting tauopathy (Braak stage
I–IV controls and IV–VI AD, Table S1) [31] were obtained
from the Newcastle Brain Tissue Resource (NBTR). All
was approved by the joint Ethics Committee of Newcastle/
North Tyneside Health Authority (following NBTR brain
banking procedures) and Tel Aviv University Ethics Com-
mittee. Full written informed consent was obtained from
tissue donors or their relatives where appropriate. All AD
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cases fulfilled the criteria for high AD neuropathological
changes according to the National Institute on Aging-Alz-
heimer's Association (NIA-AA) guidelines. Tissues were
homogenized using a Bullet Blender (Next Advance, Inc.,
NY). RNA and DNA were extracted from the same tissue
with a ZR-Duet DNA-RNA MiniPrep Plus kit (Zymo
Research, Irvine, CA).
ADNP ddPCR
20 μl ddPCR reactions were prepared (Bio-Rad Labora-
tories Ltd. Rishon Le Zion, Israel & Prague Czech
Republic): including 10 μl of ddPCR™ Supermix for
Probes (No dUTP), 1 μl of PrimePCR™ ddPCR™ Assay,
120 ng DNA, and nuclease-free water. Two targets were
detected simultaneously with different fluorescence probes:
the FAM probe detected the mutated sequence
NM_001282531.2(ADNP):c.2188C>T (p.Arg730*),
(unique assay Id: dHsaMDS971559989), or in separate
reactions, the NM_015339.3(ADNP):c.2157C>G (p.
Tyr719*) (unique assay Id: dHsaMDS423261257, supple-
mental methods). The HEX probe was used to detect the
control sequence (Gene Id: 23394). The annealing tem-
perature for various sets of primers and probes was estab-
lished by previous gradient runs. After droplet generation,
PCR was performed in a C1000 as follows, 95 °C 10 min,
40 cycles of 94 °C 30 s, 54 °C 1 min, 98 °C 10 min. The
droplets were analyzed with a QX200 instrument, and the
data were processed by the Quantasoft software, with the
rare event detection (RED) mode according to the digital
MIQE guidelines [32].
cDNA library preparation
A cDNA library was prepared from 1000 ng RNA samples
with a SMARTer® Stranded Total RNA Sample Prep Kit
—HI Mammalian (Clontech Laboratories, CA). The
SMARTer® kit is suitable for total RNA with a RIN
between 3 and 10. The cDNA library was validated using
the 4200 Tape Station System (Agilent Technologies,
Santa Clara, CA) with High Sensitivity DNA Kit. The
cDNA library was quantified using Qubit™ fluorometric
(Thermo Fisher Scientific, Waltham, MA). Four pools
were prepared from the RNA libraries (10 nM) and were
sequenced on four lanes.
RNA-Seq
cDNA sequencing was performed as a single read 60 on
four lanes of an Illumina Hi-Seq. Sequencing depth
was ~17 M reads/sample. Raw reads were processed by
trimming poly-A/T stretches and Illumina adapters
using cutadapt [33] and resulting reads shorter than 30 bp
were discarded. The trimmed reads were mapped to
the human genome (Ensembl GRCh38) using STAR
v2.4.2a [34] with default parameters (supplemental
methods).
Variant calling
Trimmed reads were mapped to the human genome
(Ensembl’s GRCh38) using STAR v2.4.2a [34] with default
parameters and twopassMode set to basic. Reads were then
deduplicated using Picard, except for the olfactory bulb
data, where it was not performed due to the short read
length (60 bp). Mapped reads were further processed with
GATK’s v.3.7 [35]. SplitNCigarReads. Next, variants were
called using GATK’s HaplotypeCaller with ploidy set to 10
except for chromosomes 10 and 15 in GSE95587, the
fusiform gyrus tissue dataset, where it was set to 8 due to
technical limitations that did not allow to use ploidy10.
Variants were filtered with the following values for SNPs
and Indels respectively: QD < 2.0, FS > 30.0, MQ < 40.0,
MQRankSum <−12.5, ReadPosRankSum <−8.0 and QD
< 2.0, FS > 30.0 and ReadPosRankSum <−20.0. DbSnp
annotation was done against dbSNP build 146 [36] and
variant annotation was done with Ensembl’s Variant Effect
Predictor v.83 [37] against GRCh38. Expression values
were calculated using RSEM with bowtie2. P-values were
calculated using Mann–Whitney (one tail) test on the
mutations frequencies between the AD subjects and healthy
aging subjects.
Gene expression omnibus (GEO) datamining
Dataset GSE95587 [38] was identified as containing a large
cohort (N= 117) with a high number of reads covering each
position (32) including AD postmortem brain tissues from
fusiform gyri section I (supplemental methods), this was
accompanied by a larger dataset GSE125583 (N= 289)
with a lower coverage (20), fusiform gyri tissue section II
(Fig. 1). Two additional libraries included GSE67333-
hippocampal RNA-seq (late onset AD) [39] and
GSE53697-DLPFC (advanced AD) [40]; however, these
two libraries should be taken cautiously due to small sample
sizes (Fig. 1). For different cell type mutation analysis, the
GSE125050 superior frontal gyrus dataset was used
including endothelial cells (CD31+), astrocytes (GFAP+)
myeloid cells (CD11b+), and neurons (NeuN+) (total
sample size 113).
Plasmid constructions
ADNP syndrome mutated cDNA inserts to be cloned
into the backbone of the vector pEGFP-C1 were obtained
from mRNA extracted from patient-derived
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lymphoblastoid cell lines carrying the following muta-
tions: c.2188C>T (p.Arg730*), c.2156_2157insA (p.
Tyr719*). The insert of full-length human ADNP was
obtained from a control lymphoblastoid cell line with no
mutation [7, 15].
Cell culture, transfection, plasmid overexpression,
and live imaging
Mouse neuroblastoma N1E-115 cells (ATCC, Bethesda,
MD) were maintained, differentiated, co-transfection with
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plasmids expressing EB3-RFP and GFP–ADNP or GFP-
mutated-ADNP) and subjected to live imaging [23].
Fluorescence recovery after photobleaching (FRAP)
Differentiated N1E-115 cells were co-transfected with
mCherry-Tau and GFP conjugated to full-length ADNP or
mutated ADNP, and imaged 48 h after transfection. An ROI
(region of interest) for photobleaching was drawn in the
proximal cell branches. mCherry-Tau was bleached with a
587 nm argon laser and fluorescence recovery was at
610–650 nm. Immediately after bleaching, 80 images were
collected every 0.74 s. Fluorescence signals were quantified
with ImageJ (NIH), obtained data were normalized with
easyFRAP [41], and FRAP recovery curves were fitted by a
two-phase exponential association function using GraphPad
Prism 6 (GraphPad software, Inc., La Jolla, CA). Samples
with R2 < 0.9 were excluded.
Statistics
Analyses (SPSS 23, Chicago, IL) for postmortem brain tissues
employed either ANOVA or Kruskal–Wallis tests (>two
groups) followed by nonparametric Mann–Whitney U test.
Multiple testing corrections employed Bonferroni. Correlations
employed Spearman. Live-cell imaging and FRAP results
were analyzed by SigmaPlot 11 (Systat Software, Inc., San
Jose, CA) with two-way ANOVA, followed by Fisher LSD.
Additional information can be found in the
Supplemental file.
Results
Somatic ADNP mutations
Given that the prevalence of ADNP mutations in autistic
children is ~1:500–1:1000 [7], we subjected AD and control
postmortem DNA samples to ddPCR and screened for the
most abundant ADNP mutations [7, 15]. These included p.
Tyr719* (22% of the current ADNP syndrome cases),
resulting from different mutations at the cDNA level—e.g.
c.2157C>G (7–11%), p.Asn832Lysfs*81 and p.Leu831I-
lefs*82 (13–16%), and p.Arg730*—c.2188C>T (6–9%).
Surprisingly, mutations were observed only in p.Arg730*,
c.2188C>T. The p.Arg730*, c.2188C>T mutation was
observed at the DNA level in the postmortem samples from
both AD and control subjects, with an insignificantly higher
prevalence in AD samples (Fig. 1a, S1-S3, Tables S1, S2).
Grouping all tested samples together (including hippo-
campal and olfactory bulb mutations w/o positive presence
of mutations with borderline values) also suggested a 2-fold
increase in the AD cases (Fig. 1b).
Public dataset validation: somatic mutations in
multiple genes with AD specificity and enhancement
To extend the single gene findings, postmortem olfactory
bulb cDNA samples (19 AD, 20 controls) all presenting
tauopathy and ~80% exhibiting amyloid pathology
(Table S1) were subjected to RNA-Seq. We then discovered
an ADNP c.2187_2188insA, p.Arg730Thrfs*4 mutation
(same position as p.Arg730*—c.2188C>T). Results were
validated by examination of reads aligned to the area of
c.2187_2188insA using Integrative Genomics Viewer
(IGV) (Fig. S4).
To extend and validate the findings for ADNP in the
olfactory bulbs (Table S3) and the hippocampus to other
brain areas we have resorted to datamining of hippocampi,
DLPFC and fusiform gyri public RNA-seq databases
(Tables S4–S6a,b). As seen in Fig. 1c, the newly discovered
mutation appeared in all tested brain regions. Furthermore, a
unique mutation appeared in the DLPFC and two additional
hot spots were discovered in the fusiform gyrus
(c.3047_3048, also seen in ADNP syndrome cases [7] and
c.64_65ins). An additional mutation in the fusiform gyri
Fig. 1 ADNP c.2188C>T, p.Arg730* mutations/AD—multiple somatic
mutations in multiple brain areas correlate with tauopathy. a, b Positive
subjects who were found to carry the ADNP c.2188C>T, p.Arg730*
mutations and negative cases who were found to be non-carriers. a
Relative fractions of ADNP c.2188C>T, p.Arg730* mutation positive
AD (black) and mutation positive controls (blue) were calculated, in each
brain region (Table S1, including 2 borderline positives). OB—olfactory
bulb and HIP—Hippocampus, results showed similar distribution in AD
and control samples. b All mutation positives (OB, HIP, and OB+HIP),
excluding borderline positives are shown (14/20; AD; 7/20 controls,
Pearson Chi-Square, *P < 0.05). It should be noted that when logistic
regression of morbidity as a function of the number of regions with
mutations was performed, the result was insignificant. c RNA-seq
identification of novel, tissue-associated ADNP-AD mutation, autism-
related ADNP mutation are marked in bold. d Mutation analysis of
RNA-seq variant calling of four postmortem brain areas: olfactory bulb
(our own primary data), Hippocampus (GSE67333), Dorsolateral pre-
frontal cortex (DLPFC) (GSE53697) and Fusiform gyrus tissue section I
(GSE95587) and Fusiform gyrus tissue section II (GSE GSE125583).
The pie charts represent distribution of mutations into three different
groups: controls (Cont.) only, AD only and both in AD+ controls (AD
+Cont.). The Box plots represent (e) mutation numbers per subject and
(f) mutation frequencies per subject for each group in the four brain
areas. Statistical analyses (Table S6b) were performed by the nonpara-
metric Kruskal–Wallis test for the hippocampus and DLPFC and
ANOVA for the olfactory bulb and the fusiform gyrus with post hoc
Bonferroni for multiple comparisons. AD-associated mutations including
AD only and AD+Cont. mutations: mutation numbers and mutation
frequencies in AD subjects were compered with aging controls. Statis-
tical analyses was done by T-Test for all calculated mutation frequencies
and T-Test for olfactory bulb and fusiform gyrus and Mann–Whitney test
for hippocampus and DLPFC for number of mutations per subject.
Statistical significance is presented by *=P < 0.05, **=P < 0.001, ***
=P < 0.0001. g Spearman correlations of mutation numbers per subject
and mutation frequencies per subject with Braak stage in control and AD
subjects grouped together
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was also seen in c.851delC. Fig. S5 shows predicted hairpin
formations by the 100 bp genomic sequence surrounding
the prevalent ADNP mutations.
In general, in the olfactory bulb we discovered 665
mutations in 596 genes with 441 mutations in AD patients
(389 genes, 38% AD—unique mutations, Fig. 1d). When
the three groups of mutations (control exclusive, shared and
AD unique mutations) were compared the number (Fig. 1e)
and frequencies (Fig. 1f) of mutations per subject were
significantly higher in the shared group of mutations. Fur-
ther comparisons of control subjects carrying AD shared
mutations to AD subjects carrying shared and unique AD
mutations showed highly significant increases in number
(Fig. 1e) and frequencies (Fig. 1f) per AD vs. control
subjects. Similar results were obtained by RNA-seq data-
mining of public datasets (hippocampus, DLPFC, and
fusiform gyrus I (142 subjects)+ an additional cohort of
fusiform gyrus II with 89 shared subjects with fusiform
gyrus I plus 200 unique subjects, Fig. 1g). (Only the
comparison concentrating on AD-mutation number per
subject in the fusiform gyrus I were similar in controls and
AD subjects). AD mutation numbers and frequencies per
subject positively correlated with tauopathy (Braak stage,
Fig. 1g and S6 except hippocampi, frequencies and fusiform
gyri, numbers). A positive correlation with amyloid beta
plaque load was measured in the olfactory bulbs (Fig. S6,
R~0.4, P < 0.05).
To correlate mutations to known diseases OMIM ana-
lysis (https://www.omim.org) was performed followed by
String analysis to identify molecular interactions. Figure 2
shows the olfactory bulb as an example with 104 genes
(30%) associated with 193 diseases (Table S3), converging
on cytoskeletal mechanisms, autism and ID causing muta-
tions (~40% each, Fig. 2a, b) with 12 gene overlap (Fig. 2b,
c, Table S7). Similar enrichments in cytoskeletal mutations
were discovered in other tested brain areas specifically in
AD-linked mutations (Fig. S7). Interestingly, several
DLPFC subjects also showed mutations in genes associated
with familial AD (amyloid precursor protein-APP and pre-
senilin 1-PSEN1 (Table S5, Fig. S7).
Overlapping of all identified mutated genes in the four
brain areas with cytoskeletal genes (Tables S3–S6a,b S8a)
revealed about 25–70% uniquely mutated and four shared
genes (Fig. 3a). Overlapping all mutated genes with
cytoskeletal genes, while not showing a proportional
increase in AD vs. control (Table S8b) did show an AD-
specific MT-based processes gene group and a control
specific gene group associated with cell projection organi-
zation (Fig. S7).
Further overlap with autism spectrum disorder (ASD, aut-
ism) database (https://gene.sfari.org/database/human-gene/)
and ID database (http://www.ccgenomics.cn/IDGenetics/gene.
php?dataset=IDGD_gene_detail) identified unique and shared
mutated gene mutations (Tables S9–S11), with ADNP singled
out as a gene associated with cytoskeleton/autism/ID/AD
(Fig. 3a, b, Table S9).
To better understand the cellular distribution of the
mutations, an additional database was mined GSE125050
[42] (Fig. 3c–e, Table S12 a, b). The results per cell mir-
rored the tissue findings (Fig. 1e, f) with neurons showing
the least mutations. Furthermore, mutation frequencies and
mutation numbers/subject were significantly correlated only
in the AD-derived cells (Fig. 3e).
IGV analysis of the large GSE95587 (fusiform gyrus I)
cohort with high sequencing coverage (Fig. 1g, Fig. S8)
revealed significantly more c.2187_2188insA ADNP
mutation carriers (~50%) among the AD subjects than
controls (15%, Fig. 3f, Table S6a, bold). Figure 3g shows
the frequency of the c.2187_2188insA, mutation to the
intact ADNP sequence within the cDNA reads. The find-
ings indicated up to ~10% mutated forms, suggestive of
somatic mutations. Comparison of controls (Braak stage
I–III) and AD (Braak stage IV–VI) revealed a significant
enrichment of ADNP mutations in AD subjects (Fig. 3h).
Subjects displaying postmortem Braak stage IV (AD and
controls) showed a similar frequency of the ADNP
c.2187_2188insA, mutation. Furthermore, a significant
correlation between the ADNP c.2187_2188insA, muta-
tion and the Braak stage was observed in control subjects
(R= 0.394, Spearman correlation, p= 0.028, n= 31,
Braak stage I–IV), Fig. 3h. Correlation was also dis-
covered between ADNP mutation frequency and the age
of death (Fig. 3i). Furthermore, ADNP mutations were
more prevalent in AD specimens compared to controls
(Table S6a, ADNP). Interestingly, our study revealed
multiple ADNP somatic mutations as outlined in Fig. 1c
and extended to include additional cellular mutations
(Fig. 3c–e, Table S13, Fig. 4a).
ADNP mutation induced tauopathy corrected by
NAP
Given the prevalence of ADNP somatic mutations in
postmortem AD brains and the potential convergence of
identified gene mutations on the cytoskeleton, we hypo-
thesized cytoskeletal damage as a consequence of ADNP
mutations. To test our hypothesis, we imaged MT
dynamics in living N1E-115 neuroblastoma cells, while
tracking the growth of individual MTs with RFP-tagged
EB3 proteins that bind to MT plus-ends. Two parameters
of EB3 mobility were used to assess MT dynamics:
growth track length, and growth track speed of EB3
comet-like structures. These parameters reflect the lengths
of the MT growing events and the speed of MT assembly,
respectively [23]. In addition, we examined whether
incubation with the MT-interacting ADNP snippet, NAP
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(10−12M, 4 h) could protect against the deleterious ADNP
mutations.
Figure 4a–c (Figs. S9–S11, movies S1–S2) show that
overexpression of full-length ADNP significantly increased
EB3 comet track length and that NAP treatment did not
further influence this increase. Expression of the ADNP p.
Arg730*, or p.Tyr719* mutations (Fig. 4a–c, Table S14,
Movies S3–S4) significantly decreased EB3 comet speeds
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and track lengths, compared to either full-length ADNP or
control plasmid (except for ADNP p.Tyr719*, where the
reduction in EB3 track length was significant compared
only to full-length ADNP). NAP treatment significantly
augmented the growth speed and track length of the EB3
comets with both mutations.
To examine the effect of full-length/truncated ADNP
forms and NAP on Tau–MT interactions, we used FRAP
(Fig. 5). The intensity of mCherry-tagged Tau protein
fluorescence recovery within a photo-bleached region of
interest (ROI) reflects the immobile fractions of bleached
molecules, which do not release binding sites on MTs for
incoming un-bleached mCherry-Tau proteins and thus do
not contribute to the fluorescence recovery. Consequently,
the immobile mCherry-Tau fraction reflects the rate of Tau
association with MTs [43].
We observed that overexpression of full-length ADNP
resulted in a minor insignificant reduction in the immobile
mCherry-Tau fraction compared to control (Fig. 5a–c), which
was not affected by NAP treatment (Fig. 5a, c, Table S14).
Importantly, both truncated forms of ADNP significantly
attenuated Tau association with MTs, compared to the GFP-
control, or full-length ADNP (Fig. 5a–c). NAP treatment
restored the Tau–MT interaction to control values (GFP and
full-length ADNP controls, Fig. 5a–c). Finally, the ability of
NAP to protect MTs against degradation by promoting
Tau–MT interaction has been previously shown in the murine
cell lines [23, 25] and confirmed here (Supplemental results,
Figs. S12–S13), in a human neuroblastoma SH-SY5Y
cell model.
Discussion
The amyloid hypothesis domineers the framework for AD
research and therapies, despite continuous clinical failures
(https://www.alzforum.org/news/research-news/
biogeneisai-halt-phase-3-aducanumab-trials). Tau-
clearance therapies [15] are also being developed, how-
ever, Tau monotherapy may not suffice [44, 45]. Impor-
tantly, it is apparent that the various tauopathies constitute
different diseases, which may require versatile treatment
modalities [15]. For example, NAP (davunetide, AL-108)
failed in the pure 4R tauopathy progressive supranuclear
palsy (PSP) [46], but showed efficacy in increasing cog-
nitive scores in patients with amnestic mild cognitive
impairment (mixed 3R+ 4R tauopathy) [15, 47] invol-
ving differential interaction with Tau 3R/4R splice var-
iants [28].
Mutations in cytoskeletal proteins may contribute only
partly to drug targeting in AD precipitation, as the plethora
of somatic pathogenic mutations may have cumulative
effects. An intriguing question is how these mutations arise.
One possibility is dysregulation of DNA proofreading,
excision or single strand repair in the face of environmental
stress coupled to random mutation accumulation during cell
divisions. While DNA repair protein mutations
(http://www.informatics.jax.org/go/term/GO:0006281) did
not appear as a major group of gene mutations in our
OMIM analyses, further tests discovered multiple DNA
repair protein mutations with shared and unique brain dis-
tribution (Table S15, fusiform gyrus showing 2-fold higher
AD mutation number vs. control, paralleling doubled
number of AD subjects, Fig. 1). Mutations included exci-
sion associated repair genes (ERCC1, XPA= ERCC2,
ERCC3, and ERCC5) only in the AD-associated fusiform
gyrus (Table S15, and Supplemental Discussion), rendering
higher sensitivity to radiation hypersensitive neurodegen-
eration [48, 49]. Similarly, lymphoblastoid cells from AD
patients are more sensitive to irradiation damage [49].
Although central and peripheral mutated genes may differ,
we have found correlations between lymphoblastoid/blood
and AD brain gene expression [50, 51]. Furthermore,
nucleotide excision repair is modulated by the mammalian
SWI/SNF chromatin-remodeling complex [52], ADNP
constitutes a part of this complex [53], and blood ADNP
levels correlate with AD [20].
Regarding cell division and potential accumulation of
mutations (paralleling with de novo mutations in autism),
adult neurogenesis drops sharply in the AD hippocampus
[2]; however, glial cells divide and may contribute to the
neuroprotective/neurodegenerative process. We now show
increased mutations in non-neuronal brain cells compared to
neurons. We singled out ADNP (a neuro-glial protein) [4]
as a case study of cytoskeleton/autism/ID/AD shared gene.
In searching for leading gene candidates for autism, others
ranked ADNP as a lead, paralleling our findings regarding
AD potentially mutated genes [8]. Our results suggest that
with aging and AD, the most significant finding in ADNP is
the p.Arg730*/p.Arg730Thrfs*4 pathogenic mutations,
Fig. 2 Somatic mutations/AD—networks in the olfactory bulb (OB). a
Interaction network by the STRING tool for 104 mutated genes with
OMIM disease association. The comparisons were made with mutated
genes, including AD specific+AD-control shared mutations. Results
of variant calling from RNA-Seq from 39 samples of OB indicated GO
molecular enrichment-Cytoskeletal protein binding (FDR= 2E-08)
colored with light purple, GO Biological process-cytoskeletal enrich-
ment-cytoskeleton organization (FDR= 2.4E-4) colored with red/
brown. GO cellular component-cytoskeleton (FDR= 8.9E-8) colored
with light blue. A total of 39 genes (38%) related to the cytoskeleton
OMIM-identified mutated genes. b Venn graph (http://www.intera
ctivenn.net/) identifying genes that are shared with Autism: https://
gene.sfari.org/database/human-gene/ and ID: http://www.ccgenomics.
cn/IDGenetics/gene.php?dataset=IDGD_gene_detail and http://
gfuncpathdb.ucdenver.edu/iddrc/iddrc/data/IDgenelist_gsym.html. c
Shared genes described in (b) are named in table (red, AD—only
mutations). Precise description of the genes can be found in Table S10
Y. Ivashko-Pachima et al.
which occur presumably somatically in selected cells, with
ADNP tightly linked to cytoskeletal regulation and dendritic
spine plasticity [14, 23, 25, 29].
Regarding the cytoskeletal mutations and disease pro-
pagation, injection of human soluble Tau into the mouse
dentate gyrus resulted in markedly reduced synapse
Somatic Mutations: A Paradigm Shift in Alzheimer's Disease Research
numbers in the hippocampal molecular layer. Soluble tau
damages the morphology and connectivity of newborn
granule cells [54] and NAP/ADNP enhance Tau–MT
association and dendritic spine formation in an EB1/EB3-
dependent manner [23, 25]. Furthermore, Tau aggregation
is inhibited by augmented autophagy [55], and ADNP/
NAP accelerate autophagy [14, 15, 19, 56–59]. As
tauopathy is suggested to propagate in a prion-like manner
[60–62], it is hypothesized that even rare occurrences of
cellular tauopathy will propagate, making prevention
therapy with NAP treatment prior to disease onset a
desired possibility. More generally, recent findings show
that the retrovirus-like Gag protein Arc1 binds RNA and
traffics across synaptic buttons, suggesting the possibility
of wide transfer of mutated disease driving RNAs [63].
The discovery of somatic mutations in genes causing
familial, amyloid-driven AD [64–66] also in our cohorts
(DLPFC, Table S5, Fig. S7) provides increased relevance
to our findings.
Our study mostly relies on RNA-seq data (partially
backed by sensitive ddPCR). A recent RNA-seq pub-
lication elegantly supports our findings revealing macro-
scopic somatic clonal expansion across normal tissues.
Furthermore, this cited study finds age-dependent
increases in clonal expansion, in agreement with our
multiple mutation discoveries in the elderly control
cohorts [67]. Together, our studies corroborate RNA-seq
results in terms of mutation analysis [67] and further
imply that accumulating mutations with aging may con-
tribute to the increased risk of AD, with aging being the
highest risk factor for AD.
Regarding prevention by NAP and related molecules
[14], our data suggested that ADNP enhanced MT
dynamics with a saturation effect, explaining previously
observed in vitro bell-shape dose dependence for NAP,
albeit, over a very broad concentrations range [4]. Our
model here for AD protection included overexpression of a
mutated ADNP in a cell expressing intact ADNP, sug-
gesting antagonistic function and competition with the
endogenous ADNP over MT association and enhancement
of MT dynamics, which is ameliorated by NAP treatment.
Indeed, our previous studies showed that NAP enhances
intact ADNP association with MTs [25] and protects against
Adnp- haploinsuffiency in mice [13]. These results pave the
path to NAP/ADNP enhancing therapy in the ADNP syn-
drome (CP201, Coronis Neurosciences) [68] and for NAP
and related molecules as preventive treatment in prodromal
AD [69].
In conclusion, we revealed somatic aging/AD-linked
mutations converging on tauopathy [70], including NAP/
ADNP [25]. We further showed a significant correlation
between the frequency of the ADNP c.2187_2188insA
mutation and aging, suggesting accumulation with aging
and increasing Braak stages, implicating either a parallel or
a causal relation, possibly linked to Tau-like prion-like
propagation [60–62]. Together, our results represent a
paradigm-shifting concept in the perception of AD,
whereby accumulating somatic gene mutations promote
brain pathology and cognitive loss, and open new horizons
for research and development.
Fig. 3 ADNP mutations are shared by all tested brain regions and
cytoskeletal proteins/ID/autism, ADNP c.2187_2188insA correlate
with AD tauopathy. a, b Venn graphs (http://www.interactivenn.net/)
showing comparisons of mutated genes, including AD specific+ AD-
control shared mutations, from four postmortem brain areas: olfac-
tory bulb, Hippocampus (GSE67333), dorsolateral prefrontal cortex
(DLPFC) (GSE53697) and fusiform gyrus (GSE95587) shared with
a cytoskeletal genes (GO:020954 and GO:020801), b Autism and ID
genes. Note, the numbers of mutated genes are lower than the
numbers depicted in Fig. 1d as there are shared genes between AD-
specific and AD+ controls shared mutations, however, the mutations/
gene are unique in the two different groups. c Mutation analysis of
RNA-seq variant calling of postmortem superior frontal gyrus from
different cell types: Endothelial (CD31+), Astrocyte (GFAP+)
Myeloid (CD11B+) and Neuron (NeuN+) (GSE125050). The
mutations were devided into three different groups: Controls (Cont.)
only, AD only and both in AD+ controls (AD+Cont.). The Box
plots represent number of mutations per subject and frequencies of
mutations per subject for each group in all cell types. AD-associated
mutations including AD only and AD+Cont. mutations: mutation
numbers and mutation frequencies in AD subjects were compered
with controls. Statistical analyses (Table S12b) were performed by
the nonparametric Kruskal–Wallis test for mutation numbers with
post hoc Bonferroni for multiple comparisons. For all mutation fre-
quencies ANOVA were performed with post hoc Bonferroni for
multiple comparisons. AD-associated mutations including AD only
and AD+Cont. mutations: statistical analyses were done by T-Test
for all calculated mutation frequencies and for the average mutations
number per subject. The Kolmogorov–Smirnov test of normality was
used to test normal distribution. Statistical significance is presented
by *= P < 0.05, **= P < 0.001, ***= P < 0.0001. d The table
represents the distribution of mutations in different cell types.
e Pearson correlations of mutation numbers per subject with mutation
frequencies per subject in control and AD subjects in all cell types
grouped together are shown. f Percentage of ADNP
c.2187_2188insA, p.Arg730Thrfs*4 mutation positive AD (black)
and mutation positive controls (blue) in the respective tested popu-
lations were calculated showing significantly higher mutation fre-
quency in AD samples (Braak stage IV–VI) compared to age-
matched controls (Braak stage I-III) (Pearson Chi-Square, P=
0.007). Positive cases are subjects who were found to carry the
c.2187_2188insA, p.Arg730Thrfs*4, in the GEO database
GSE95587 (postmortem fusiform gyrus tissue sections, see Fig. S8).
g c.2187_2188insA, p.Arg730Thrfs*4 mutation frequency to the
intact ADNP sequence within the cDNA reads, shows a significant
differences between controls (blue) and AD (black) samples, one
tailed Mann–Whitney Test, P= 0.006. h ADNP c.2187_2188insA,
p.Arg730Thrfs*4 mutation positive showing mutation frequency to
intact ADNP (as in g) for all the different Braak stages (control—
blue, AD-black) with increased mutation frequency in the control
correlated with increased Braak stage, Spearman correlation, R=
0.394, P= 0.028. i Pearson correlation between ADNP mutation
ratio and age of death in AD
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Fig. 4 ADNP mutations inhibit MT dynamics, NAP protects. a
Location of functional protein regions are depicted along full-length
human ADNP coding sequence. The arrows point out all ADNP
mutations identified in the current study, including the mutations that
were examined below. The figure was constructed according pre-
viously published data [4–7, 11, 19, 21, 25, 53, 71–75]. b Live ima-
ging of N1E-115 cells expressing EB3-RFP with GFP conjugated to
full-length ADNP or truncated ADNP proteins with or without NAP
treatment (10−12M) for 4 h. Transfection with backbone plasmid
(pEGFP-C1) expressing non-conjugated GFP, was performed as a
control. Time-lapse images were automatically captured every 3 s
during a 1 min using the Leica LAS AF software. Tracks of EB3
comet-like structures presented as colored lines and were obtained by
the Imaris software. c Graphs represent quantification of the average
track length and comet speed. Data from three independent experi-
ments were collected in unbiased fashion by the Imaris software, and
statistical analysis (Table S14) of the data was performed by Two-Way
ANOVA (SigmaPlot11). Statistical significance is presented by *P <
0.05, **P < 0.01, ***P < 0.001. Control n= 26; Control+NAP n=
11; full-length ADNP n= 28; full-length ADNP +NAP n= 28; p.
Arg730* n= 43; p.Arg730* +NAP n= 20; p.Tyr719* n= 32; p.
Tyr719*+NAP n= 30
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